The ESMO 2026 presentation on October 24 is the nearer-term catalyst — three-year monotherapy data will be closely watched for durability and standalone efficacy. SITC data in November adds immunology depth. Both events are binary for a pre-revenue biotech; positive data could drive significant upside, while negative or mixed results would be bearish.
Price Chart
Executive Summary
Evaxion announced it will present new immune data from the Phase 2 trial of its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting (November 4-8), including both an oral and poster presentation. The data will focus on systemic immunomodulatory effects beyond vaccine-specific T-cell responses. This follows the upcoming three-year clinical update at ESMO 2026 on October 24, which will provide standalone EVX-01 efficacy data after patients discontinued pembrolizumab. The filing is a routine pipeline update with no new clinical results disclosed, but the upcoming data catalysts (ESMO and SITC) represent near-term binary events for this clinical-stage biotech.
Key Facts
- Evaxion will present new immune data for EVX-01 at SITC 2026 (Nov 4-8) in both oral and poster format.
- The data will cover systemic immunomodulatory effects of EVX-01 plus pembrolizumab in advanced melanoma.
- Complete three-year Phase 2 clinical data will be presented at ESMO 2026 on October 24, 2026.
- Two-year data showed 75% ORR (12/16 patients), 4 complete responses, 92% ongoing response at 2 years, and no relapses.
- In year 3, patients received EVX-01 as monotherapy, providing insight into vaccine effect without anti-PD-1.
- EVX-01 is Evaxion's lead clinical asset, a personalized peptide-based cancer vaccine for advanced solid tumors.
Financial Impact
No financial data disclosed; pre-revenue clinical-stage company. Upcoming ESMO and SITC data presentations are potential catalysts for valuation.
Risk Factors
- No new clinical data disclosed in this filing; the market impact depends entirely on the ESMO and SITC presentations.
- EVX-01 is still in Phase 2 with only 16 patients — small sample size limits statistical reliability and generalizability.
- Pre-revenue company with no approved products; requires additional capital to fund operations and trials.
- Forward-looking statements highlight risks including need for capital, clinical trial success, and dependence on partnerships.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006353 |
| Document: f6k_100226.htm | 0001171843-26-006353 |
| Document: 0001171843-26-006353-index-headers.html | 0001171843-26-006353 |
| Document: 0001171843-26-006353-index.html | 0001171843-26-006353 |
| Document: 0001171843-26-006353.txt | 0001171843-26-006353 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $3.76 $3.08 | ▼ −18.09% | ▼ −18.80% | $3.04 (−19.15%) |
Oct 19, 2026 8d ago | 6-K | $3.33 $4.05 | ▲ +21.62% | ▲ +21.29% | $3.04 (−8.71%) |
Oct 2, 2026 25d ago | 6-K | $3.20 $3.15 | ▼ −1.56% | ▼ −2.24% | $3.04 (−5.00%) |
Oct 2, 2026 25d ago | Press Release | $3.20 $3.15 | ▼ −1.56% | ▼ −2.24% | $3.04 (−5.00%) |
Sep 14, 2026 6w ago | 6-K | $3.07 $3.04 | ▼ −0.98% | ▼ −0.52% | $3.04 (−0.98%) |
Sep 4, 2026 7w ago | 6-K | $3.12 $3.17 | ▼ −1.60% | ▼ −2.15% | $3.04 (+2.56%) |
Aug 20, 2026 9w ago | 6-K | $3.28 $3.31 | ▲ +0.91% | ▲ +0.51% | $3.04 (−7.32%) |
Aug 20, 2026 9w ago | Press Release | $3.28 $3.31 | ▲ +0.91% | ▲ +0.51% | $3.04 (−7.32%) |
Aug 17, 2026 10w ago | 6-K | $3.13 $3.15 | ▲ +0.64% | ▲ +1.31% | $3.04 (−2.88%) |
Aug 14, 2026 10w ago | 6-K | $3.34 $3.13 | ▼ −6.29% | ▼ −5.81% | $3.04 (−8.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers